trending Market Intelligence /marketintelligence/en/news-insights/trending/1j1r58uchbrqqmml5hfc5q2 content esgSubNav
In This List

CRISPR Therapeutics chief legal officer retires

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


CRISPR Therapeutics chief legal officer retires

Zug, Switzerland-based CRISPR Therapeutics AG said Tyler Dylan-Hyde retired as chief legal officer of the company.

Dylan-Hyde joined the company in January 2015.

The company develops gene-editing therapies for various diseases, including sickle cell disease and hemophilia.